Volume 19, Number 3—March 2013
Melioidosis and Hairy Cell Leukemia in 2 Travelers Returning from Thailand
To the Editor: Patients with underlying medical conditions travel more than ever (1), and such travelers may be exposed to uncommon infections (2). We report 2 cases of melioidosis and hairy cell leukemia in travelers returning from Thailand.
Case-patient 1 was a 48-year-old man hospitalized in Paris with fever, asthenia, chills, and pancytopenia after returning from a 1-week visit to Thailand where he had been in flooded regions (Koh Samui and Koh Samet). Clinical examination showed a temperature of 40°C and mucocutaneous pallor. Laboratory tests showed a hemoglobin level of 7.9 g/dL, a platelet count of 33 × 109/L, a leukocyte count of 1.3 × 109 cells/L, a polymorphonuclear cell count of 0.77 × 109 cells/L, a monocyte count of 0, and a C-reactive protein level of 158 mg/L. Results of tests for HIV, dengue, and malaria were negative.
Presumptive antimicrobial drug treatment with piperacillin/tazobactam (12 g/1.5 g/d) was initiated at admission. A blood smear showed 10% hairy cells, and a bone marrow biopsy confirmed a diagnosis of hairy cell leukemia and interstitial infiltration of CD20-positive, monoclonal antibody DBA.44–positive, and tartrate-resistant acid phosphatase–positive cells.
Because of persistent unexplained fever, full-body computed tomography (CT) was performed and showed multiple liver, spleen, and lung abscesses (Figure, panels A and B). Culture of a CT scan–guided liver abscess puncture specimen was positive for Bukholderia pseudomallei after 12 days of antimicrobial drug treatment. Treatment was changed to ceftazidime (120 mg/kg/d) and trimethoprim/sulfamethoxazole (TMP/SMX) (10/50 mg/kg/d), and oral doxycycline (200 m/d) for 3 weeks. The outcome was good.
Oral treatment with TMP/SMX and doxycycline (200 mg/d) was continued for 20 weeks. Treatment for hairy cell leukemia with cladribine was initiated after 10 weeks of antimicrobial drug treatment. Two years later, the patient showed complete remission of hairy cell leukemia and melioidosis.
Case-patient 2 was a 64-year-old man hospitalized in Paris for persistent fever 16 days after his return from Thailand. Two months earlier in Thailand, he had received treatment for hepatosplenic melioidosis with ceftazidime (120 mg/kg/d), TMP/SMX (10/50 mg/kg/d), and doxycycline (200 mg/d) for 15 days, and then oral amoxicillin/clavulanic acid (3 g/d) for 3 months. At admission, he had fever, chills, abdominal pain, and cough. Clinical examination showed a temperature of 40°C and left lung crackles. Chest and abdomen CT images showed a focus of lung consolidations (Figure, panels C and D), left pleural effusion, pericarditis, and spleen abscesses. Laboratory tests showed a leukocyte count of 1.05 × 109 cells/L, a monocyte count of 0.04 × 109 cells/L, a hemoglobin level of 7.9 g/dL, a platelet count of 62 × 109/L, and a serum ferritin level of 8,530 IU/L.
Blood cultures were positive for B. pseudomallei. The strain was sensitive to amoxicillin/clavulanic acid. Bone marrow aspiration and biopsy showed hemophagocytosis and interstitial infiltration of CD20-positive, monoclonal antibody DBA.44–positive, CD 103-positive, CD25-positive, CD11c-positive, and CD123-positive cells, leading to a diagnosis of hairy cell leukemia. The patient was given a 2-week course of intravenous TMP/SMX (10 mg/50 mg/kg/d), oral doxycycline (200 mg/d), and intravenous ceftazidime (120 mg/kg/d), followed by a 6-month course of oral TMP/SMX (50 mg/10 mg/kg/d) and doxycycline (4 mg/kg/d). The condition of the patient improved and pancytopenia resolved. Thus, he did not require any treatment for hairy cell leukemia. No relapse of melioidosis occurred.
Melioidosis is endemic to the Pacific region and Southeast Asia (3,4). Most cases reported in other regions are imported (5). In Thailand, where both patients had traveled, the number of cases increased from 11.5/100,000 inhabitants in 1997 to 21.3/100,000 in 2006 (6). The 2 main routes of transmission are transcutaneous and aerosols. Natural disasters, such as flooding, are a risk factor for melioidosis, as for case-patient 1.
This disease has an overall mortality rate of 50%. The clinical spectrum ranges from acute septicemia (mortality rate 80%) to the subacute form. B. pseudomallei is difficult to detect by culture of biologic samples, and serologic analysis or PCR for this bacteria are not routinely available. Therefore, a diagnosis of melioidosis can be easily missed.
Melioidosis occurs mainly in patients with underlying diseases such as diabetes (37%–60% of cases), chronic alcoholism (12%–39%), thalassemia, and chronic nephropathy, and in persons receiving long-term corticosteroid treatment (7). Reports of patients with melioidosis and hematologic malignancies or solid cancers are scarce (4,5,7). Hairy cell leukemia could now be included in this group of diseases.
Hairy cell leukemia is a rare chronic B-cell lymphoproliferative disorder characterized by pancytopenia; splenomegaly; and infiltration of the bone marrow, spleen, and liver by malignant B cells that have hair-like cytoplasmic projections (8,9). The incidence of hairy cell leukemia is <1 case/100,000 population/year, and the disease accounts for ≈2%–3% of all leukemias in adults in the United States (8). Infections are a common complication for patients with this disease (10).
These 2 cases of imported melioidosis show that travelers with hematologic malignancies are at risk for such infections (1). Immunocompromised travelers might be first sentinels for ongoing endemic diseases. When travelers return with uncommon diseases, physicians should check for underlying diseases. Physicians providing care for patients with hairy cell leukemia should be aware of the risk for contracting melioidosis.
We thank Laurent Meyer for reviewing the manuscript.
- Wieten RW, Leenstra T, Goorhuis A, van Vugt M, Grobusch MP. Health risks of travelers with medical conditions: a retrospective analysis. J Travel Med. 2012;19:104–10 and.
- McCarthy AE, Mileno MD. Prevention and treatment of travel-related infections in compromised hosts. Curr Opin Infect Dis. 2006;19:450–5 and.
- Cheng AC, Currie BJ. Melioidosis: epidemiology, pathophysiology, and management. Clin Microbiol Rev. 2005;18:383–416 and.
- White NJ. Melioidosis. Lancet. 2003;361:1715–22 and.
- Cahn A, Koslowsky B, Nir-Paz R, Temper V, Hiller N, Karlinsky A, Imported melioidosis, Israel, 2008. Emerg Infect Dis. 2009;15:1809–11 and.
- Limmathurotsakul D, Wongratanacheewin S, Teerawattanasook N, Wongsuvan G, Chaisuksant S, Chetchotisakd P, Increasing incidence of human melioidosis in northeast Thailand. Am J Trop Med Hyg. 2010;82:1113–7 and.
- Salam AP, Khan N, Malnick H, Kenna DT, Dance DA, Klein JL. Melioidosis acquired by traveler to Nigeria. Emerg Infect Dis. 2011;17:1296–8 and.
- Goodman GR, Bethel KJ, Saven A. Hairy cell leukemia: an update. Curr Opin Hematol. 2003;10:258–66 and.
- Bouroncle BA, Wiseman BK, Doan CA. Leukemic reticuloendotheliosis. Blood. 1958;13:609–30 .
- Kraut E. Infectious complications in hairy cell leukemia. Leuk Lymphoma. 2011;52(Suppl 2):50–2 and.
- Figure. . . Computed tomography (CT) images of the chest and abdomen of case-patient 1 showing A) a subpleural nodular and cavitary lesion (arrow) in the left upper lobe of the...
Suggested citation for this article: Rossi B, Epelboin L, Jauréguiberry S, Lecso M, Roos-Weil D, Gabarre J, et al. Melioidosis and hairy cell leukemia in 2 travelers returning from Thailand [letter]. Emerg Infect Dis [Internet]. 2013 Mar [date cited]. http://dx.doi.org/10.3201/eid1903.121329
1These authors contributed equally to this article.
Please use the form below to submit correspondence to the authors or contact them at the following address:
Loïc Epelboin, Service des Maladies Infectieuses et Tropicales, Groupe Hospitalier Pitié-Salpêtrière, 47–83 Blvd de l’Hôpital, 75013 Paris, France
Comment submitted successfully, thank you for your feedback.
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
- Page created: February 12, 2013
- Page last updated: February 12, 2013
- Page last reviewed: February 12, 2013
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)